Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients
Allergy2018Vol. 73(6), pp. 1254–1262
Citations Over TimeTop 10% of 2018 papers
Ralph Mösges, AF Koch, E Raskopf, Jagdeep Singh, Kija Shah‐Hosseini, A. Astvatsatourov, B. Hauswald, Yury M. Yarin, Francis Corazza, L. Haazen, Sabine Pirotton, Silke Allekotte, Gregor Zadoyan, Thierry Legon, Stephen R. Durham, Mohamed H. Shamji
Abstract
Increasing doses of subcutaneous LPP appeared safe, substantially diminished reactivity to CPT and induced blocking antibodies as early as 4 weeks after treatment initiation. The benefit/risk balance of LPP immunotherapy remains to be further evaluated in large studies.
Related Papers
- → Molecular Allergen-Specific IgE Recognition Profiles and Cumulative Specific IgE Levels Associated with Phenotypes of Cat Allergy(2022)21 cited
- → Can Immunoglobulin E-measurement replace challenge tests in allergic rhinoconjunctivits to grass pollen?(2011)20 cited
- → The correlation between skin tests, bronchial provocation tests and the serum level of IgE specific for common allergens in patients with asthma(1975)134 cited
- → BRONCHIAL PROVOCATION TESTS IN ATOPIC PATIENTS WITH ALLERGEN-SPECIFIC IgG4 ANTIBODIES(1982)66 cited
- → Immune Responses to Allergens in Atopic Disease: Considerations for Bioinformatics(2015)